Vertex Pharmaceuticals Incorporated Company Profile (NASDAQ:VRTX)

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated logoVertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. Its marketed medicines are ORKAMBI and KALYDECO, which are approved to treat patients with CF having specific mutations in their CF transmembrane conductance regulator (CFTR) gene. It has multiple development programs in the field of CF, including VX-661, VX-371, and VX-152 and VX-440. It is engaged in various other research and mid- and early-stage development programs, such as programs in the areas of oncology, pain and neurology. Its oncology drug candidates include VX-970, VX-803 and VX-984; pain drug candidates include VX-150 and VX-241, and acute spinal cord injury drug candidate include VX-210.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: VRTX
  • CUSIP: 92532F10
Key Metrics:
  • Previous Close: $88.33
  • 50 Day Moving Average: $84.02
  • 200 Day Moving Average: $86.58
  • 52-Week Range: $71.46 - $103.73
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 30.25
  • P/E Growth: 0.78
  • Market Cap: $21.93B
  • Outstanding Shares: 248,300,000
  • Beta: 0.79
  • Net Margins: -6.76%
  • Return on Equity: -2.15%
  • Return on Assets: -0.98%
  • Debt-to-Equity Ratio: 0.03%
  • Current Ratio: 2.08%
  • Quick Ratio: 1.98%
Additional Links:
Companies Related to Vertex Pharmaceuticals Incorporated:

Analyst Ratings

Consensus Ratings for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) (?)
Ratings Breakdown: 14 Hold Ratings, 11 Buy Ratings
Consensus Rating:Hold (Score: 2.44)
Consensus Price Target: $102.28 (15.79% upside)

Analysts' Ratings History for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
DateFirmActionRatingPrice TargetDetails
2/11/2017Cowen and CompanySet Price TargetHold$75.00View Rating Details
2/10/2017Robert W. BairdReiterated RatingOutperform -> PositiveView Rating Details
2/3/2017Maxim GroupReiterated RatingHoldView Rating Details
1/26/2017HC WainwrightSet Price TargetHold$85.00View Rating Details
1/26/2017Stifel NicolausLower Price TargetBuy$108.00 -> $100.00View Rating Details
1/20/2017Needham & Company LLCReiterated RatingHoldView Rating Details
1/9/2017JMP SecuritiesDowngradeMarket PerformView Rating Details
1/8/2017Jefferies Group LLCReiterated RatingBuyView Rating Details
1/3/2017J P Morgan Chase & CoReiterated RatingBuyView Rating Details
12/25/2016Piper Jaffray CompaniesSet Price TargetBuy$129.00View Rating Details
12/20/2016Credit Suisse GroupSet Price TargetBuy$100.00View Rating Details
12/15/2016Oppenheimer Holdings, Inc.Initiated CoverageMarket PerformView Rating Details
12/7/2016Janney Montgomery ScottReiterated RatingNeutral$98.00View Rating Details
11/30/2016BMO Capital MarketsReiterated RatingMarket Perform$88.00View Rating Details
11/29/2016Barclays PLCDowngradeOverweight -> Equal Weight$100.00 -> $90.00View Rating Details
11/1/2016William BlairDowngradeOutperform -> Market Perform$105.00 -> $81.00View Rating Details
10/26/2016Leerink SwannReiterated RatingOutperform$112.00 -> $111.00View Rating Details
10/12/2016RBC Capital MarketsReiterated RatingBuyView Rating Details
9/13/2016Citigroup Inc.Initiated CoverageMarket PerformView Rating Details
9/13/2016Raymond James Financial, Inc.Initiated CoverageMarket PerformView Rating Details
7/28/2016Morgan StanleyLower Price TargetOverweight$140.00 -> $139.00View Rating Details
4/28/2016Goldman Sachs Group, Inc. (The)DowngradeBuy -> Neutral$109.00 -> $88.00View Rating Details
4/28/2016Royal Bank Of CanadaLower Price TargetOutperform$135.00 -> $115.00View Rating Details
3/28/2016GuggenheimLower Price TargetBuy$145.00 -> $114.00View Rating Details
3/15/2016Bank of America CorpReiterated RatingNeutral$108.00View Rating Details
2/4/2016ArgusLower Price TargetBuy$154.00 -> $140.00View Rating Details
9/15/2015NomuraInitiated CoverageBuy$162.00View Rating Details
7/31/2015Deutsche Bank AGReiterated RatingBuy$155.00View Rating Details
7/7/2015BTIG ResearchLower Price TargetBuy$200.00 -> $180.00View Rating Details
6/5/2015Canaccord GenuityReiterated RatingBuy$150.00View Rating Details
(Data available from 2/21/2015 forward)


Earnings History for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/25/2017Q4 2016$0.29$0.35$453.40 million$458.71 millionViewN/AView Earnings Details
10/25/2016Q316$0.18$0.16$423.53 million$413.78 millionViewListenView Earnings Details
7/27/2016Q216$0.21$0.24$428.08 million$431.61 millionViewListenView Earnings Details
4/27/2016Q116$0.29$0.09$439.94 million$398.10 millionViewListenView Earnings Details
1/27/2016Q4$0.17$0.17$406.30 million$417.94 millionViewListenView Earnings Details
10/28/2015Q315($0.60)($0.13)$245.84 million$309.82 millionViewListenView Earnings Details
7/29/2015Q215($0.58)($0.54)$149.49 million$166.00 millionViewListenView Earnings Details
4/29/2015Q115($0.75)($0.62)$142.38 million$138.51 millionViewListenView Earnings Details
1/28/2015Q414($0.65)($0.55)$137.50 million$144.56 millionViewListenView Earnings Details
10/28/2014Q314($0.62)($0.37)$146.20 million$179.00 millionViewN/AView Earnings Details
7/29/2014Q214($0.71)($0.61)$131.85 million$138.42 millionViewListenView Earnings Details
5/1/2014Q114($0.68)($0.65)$134.46 million$118.50 millionViewN/AView Earnings Details
1/29/2014Q413($0.49)($0.56)$221.08 million$351.20 millionViewListenView Earnings Details
10/29/2013Q413($0.33)($0.32)$278.80 million$222.00 millionViewN/AView Earnings Details
7/29/2013Q2 2013($0.18)($0.26)$308.02 million$310.80 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.06)$0.03$307.85 million$328.40 millionViewN/AView Earnings Details
1/29/2013Q4 2012($0.07)($0.35)$318.53 million$334.00 millionViewN/AView Earnings Details
11/1/2012Q312$0.34$0.13$377.14 million$336.00 millionViewN/AView Earnings Details
7/30/2012$0.68$0.46ViewN/AView Earnings Details
4/26/2012$0.57$0.43ViewN/AView Earnings Details
2/2/2012$0.76$0.74ViewN/AView Earnings Details
10/27/2011$0.17$0.70ViewN/AView Earnings Details
7/28/2011($1.00)($0.67)ViewN/AView Earnings Details
5/3/2011($1.09)($0.91)ViewN/AView Earnings Details
2/3/2011($0.93)($0.74)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Current Year EPS Consensus Estimate: $1.67 EPS
Next Year EPS Consensus Estimate: $2.92 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20161($0.09)($0.09)($0.09)
Q4 20163($0.07)$0.05$0.01
Q1 20172$0.03$0.03$0.03
Q2 20172$0.02$0.07$0.05
Q3 20171$0.09$0.09$0.09
Q4 20171$0.33$0.33$0.33
(Data provided by Zacks Investment Research)


Dividend History for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Insider Ownership Percentage: 1.90%
Institutional Ownership Percentage: 94.85%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/11/2017Joshua S BogerDirectorSell8,000$82.48$659,840.00View SEC Filing  
1/4/2017Joshua S BogerDirectorSell6,500$77.13$501,345.00View SEC Filing  
12/29/2016Joshua S BogerDirectorSell6,500$74.33$483,145.00View SEC Filing  
12/21/2016Joshua S BogerDirectorSell6,500$74.16$482,040.00View SEC Filing  
12/14/2016Joshua S BogerDirectorSell6,500$77.52$503,880.00View SEC Filing  
11/30/2016Joshua S BogerDirectorSell6,500$83.48$542,620.00View SEC Filing  
11/23/2016Joshua S BogerDirectorSell6,500$86.47$562,055.00View SEC Filing  
11/16/2016Joshua S BogerDirectorSell6,500$91.55$595,075.00View SEC Filing  
11/10/2016Paul M SilvaSVPSell5,062$90.98$460,540.76View SEC Filing  
11/9/2016Joshua S BogerDirectorSell6,500$90.98$591,370.00View SEC Filing  
11/9/2016Stuart A ArbuckleEVPSell1,208$90.00$108,720.00View SEC Filing  
11/2/2016Joshua S BogerDirectorSell6,500$77.75$505,375.00View SEC Filing  
10/26/2016Joshua S BogerDirectorSell6,500$79.26$515,190.00View SEC Filing  
10/19/2016Joshua S BogerDirectorSell6,500$81.84$531,960.00View SEC Filing  
10/12/2016Joshua S BogerDirectorSell6,500$81.14$527,410.00View SEC Filing  
10/5/2016Joshua S BogerDirectorSell6,500$87.44$568,360.00View SEC Filing  
10/3/2016Stuart A ArbuckleEVPSell1,208$86.46$104,443.68View SEC Filing  
9/28/2016Joshua S BogerDirectorSell6,500$88.15$572,975.00View SEC Filing  
9/21/2016Joshua S BogerDirectorSell6,500$90.82$590,330.00View SEC Filing  
9/14/2016Joshua S BogerDirectorSell6,500$92.37$600,405.00View SEC Filing  
9/7/2016Joshua S BogerDirectorSell6,500$95.66$621,790.00View SEC Filing  
8/31/2016Joshua S BogerDirectorSell6,500$94.62$615,030.00View SEC Filing  
8/24/2016Joshua S BogerDirectorSell7,500$100.46$753,450.00View SEC Filing  
8/22/2016Joshua S BogerDirectorSell1,100$100.79$110,869.00View SEC Filing  
8/17/2016Joshua S BogerDirectorSell6,900$99.63$687,447.00View SEC Filing  
8/11/2016Joshua S BogerDirectorSell900$100.19$90,171.00View SEC Filing  
8/10/2016Joshua S BogerDirectorSell7,100$100.24$711,704.00View SEC Filing  
8/3/2016Joshua S BogerDirectorSell47,000$100.66$4,731,020.00View SEC Filing  
7/27/2016Joshua S BogerDirectorSell6,500$95.93$623,545.00View SEC Filing  
7/20/2016Joshua S BogerDirectorSell6,500$90.33$587,145.00View SEC Filing  
7/13/2016Joshua S BogerDirectorSell6,500$88.81$577,265.00View SEC Filing  
7/6/2016Joshua S BogerDirectorSell5,140$88.99$457,408.60View SEC Filing  
6/29/2016Joshua S BogerDirectorSell5,130$84.82$435,126.60View SEC Filing  
6/22/2016Joshua S BogerDirectorSell5,130$86.61$444,309.30View SEC Filing  
6/15/2016Joshua S BogerDirectorSell5,130$91.18$467,753.40View SEC Filing  
6/8/2016Joshua S BogerDirectorSell5,130$94.95$487,093.50View SEC Filing  
6/1/2016Joshua S BogerDirectorSell5,130$93.65$480,424.50View SEC Filing  
5/25/2016Joshua S BogerDirectorSell5,130$89.09$457,031.70View SEC Filing  
5/18/2016Joshua S BogerDirectorSell5,130$81.18$416,453.40View SEC Filing  
5/16/2016Amit SachdevEVPSell117$81.67$9,555.39View SEC Filing  
5/16/2016Ian F SmithCFOSell202$82.06$16,576.12View SEC Filing  
5/11/2016Joshua S BogerDirectorSell5,130$86.50$443,745.00View SEC Filing  
5/9/2016Paul M SilvaSVPSell3,000$87.63$262,890.00View SEC Filing  
5/4/2016Joshua S BogerDirectorSell5,130$81.02$415,632.60View SEC Filing  
4/27/2016Joshua S BogerDirectorSell5,130$83.67$429,227.10View SEC Filing  
4/20/2016Joshua S BogerDirectorSell5,130$84.10$431,433.00View SEC Filing  
4/13/2016Joshua S BogerDirectorSell5,130$84.27$432,305.10View SEC Filing  
4/6/2016Joshua S BogerDirectorSell5,130$89.56$459,442.80View SEC Filing  
3/30/2016Joshua S BogerDirectorSell5,130$78.83$404,397.90View SEC Filing  
3/23/2016Joshua S BogerDirectorSell5,130$81.38$417,479.40View SEC Filing  
3/16/2016Joshua S BogerDirectorSell5,130$79.65$408,604.50View SEC Filing  
3/2/2016Joshua S BogerDirectorSell5,130$91.80$470,934.00View SEC Filing  
2/24/2016Joshua S BogerDirectorSell5,130$85.25$437,332.50View SEC Filing  
2/17/2016Joshua S. BogerDirectorSell5,130$86.93$445,950.90View SEC Filing  
2/10/2016Joshua S. BogerDirectorSell5,130$82.57$423,584.10View SEC Filing  
2/3/2016Ian F. SmithCFOSell12,084$90.84$1,097,710.56View SEC Filing  
2/3/2016Jeffrey M. LeidenCEOSell9,834$90.82$893,123.88View SEC Filing  
2/3/2016Joshua S. BogerDirectorSell5,130$90.81$465,855.30View SEC Filing  
2/3/2016Paul M. SilvaSVPSell5,062$90.82$459,730.84View SEC Filing  
2/3/2016Stuart A. ArbuckleEVPSell6,042$90.82$548,734.44View SEC Filing  
2/2/2016Jeffrey ChodakewitzCMOSell2,375$91.38$217,027.50View SEC Filing  
1/27/2016Joshua S. BogerDirectorSell11,200$93.22$1,044,064.00View SEC Filing  
1/20/2016Joshua S. BogerDirectorSell10,400$93.69$974,376.00View SEC Filing  
1/13/2016Joshua S. BogerDirectorSell10,400$98.41$1,023,464.00View SEC Filing  
1/6/2016Joshua S. BogerDirectorSell10,400$121.96$1,268,384.00View SEC Filing  
1/4/2016Yuchun LeeDirectorSell1,125$122.21$137,486.25View SEC Filing  
12/30/2015Joshua S. BogerDirectorSell10,400$127.15$1,322,360.00View SEC Filing  
12/21/2015Joshua S. BogerDirectorSell10,400$119.26$1,240,304.00View SEC Filing  
12/9/2015Joshua S. BogerDirectorSell10,400$120.80$1,256,320.00View SEC Filing  
12/4/2015Stuart A. ArbuckleEVPSell4,531$123.98$561,753.38View SEC Filing  
12/2/2015Joshua S. BogerDirectorSell10,400$130.91$1,361,464.00View SEC Filing  
12/1/2015David AltshulerEVPSell5,000$131.00$655,000.00View SEC Filing  
12/1/2015Yuchun LeeDirectorSell1,125$129.65$145,856.25View SEC Filing  
11/23/2015Joshua S. BogerDirectorSell10,400$132.18$1,374,672.00View SEC Filing  
11/11/2015Joshua S. BogerDirectorSell10,400$118.59$1,233,336.00View SEC Filing  
11/4/2015Joshua S. BogerDirectorSell10,400$124.23$1,291,992.00View SEC Filing  
11/2/2015Yuchun LeeDirectorSell1,125$126.19$141,963.75View SEC Filing  
10/28/2015Joshua S. BogerDirectorSell10,400$119.01$1,237,704.00View SEC Filing  
10/21/2015Joshua S. BogerDirectorSell10,400$108.82$1,131,728.00View SEC Filing  
10/14/2015Joshua S. BogerDirectorSell10,400$112.62$1,171,248.00View SEC Filing  
10/7/2015Joshua S. BogerDirectorSell10,400$109.61$1,139,944.00View SEC Filing  
10/2/2015Elaine UllianDirectorSell20,000$110.00$2,200,000.00View SEC Filing  
10/1/2015Stuart A. ArbuckleEVPSell12,417$104.71$1,300,184.07View SEC Filing  
10/1/2015Yuchun LeeDirectorSell1,125$104.64$117,720.00View SEC Filing  
9/30/2015Joshua S. BogerDirectorSell10,400$103.14$1,072,656.00View SEC Filing  
9/23/2015Joshua S. BogerDirectorSell10,400$111.89$1,163,656.00View SEC Filing  
9/16/2015Joshua S. BogerDirectorSell10,400$133.24$1,385,696.00View SEC Filing  
9/9/2015Joshua S. BogerDirectorSell10,400$131.41$1,366,664.00View SEC Filing  
9/4/2015Stuart A. ArbuckleEVPSell9,063$125.77$1,139,853.51View SEC Filing  
9/2/2015Joshua S. BogerDirectorSell10,400$125.85$1,308,840.00View SEC Filing  
9/1/2015Yuchun LeeDirectorSell1,125$125.40$141,075.00View SEC Filing  
8/26/2015Joshua S. BogerDirectorSell10,400$124.71$1,296,984.00View SEC Filing  
8/19/2015Joshua S. BogerDirectorSell10,400$139.93$1,455,272.00View SEC Filing  
8/12/2015Joshua S BogerDirectorSell10,400$135.83$1,412,632.00View SEC Filing  
7/22/2015Joshua S BogerDirectorSell10,400$130.92$1,361,568.00View SEC Filing  
7/15/2015Joshua S BogerDirectorSell12,200$133.98$1,634,556.00View SEC Filing  
7/13/2015Paul M SilvaSVPSell1,125$123.79$139,263.75View SEC Filing  
7/8/2015Joshua S BogerDirectorSell11,700$122.74$1,436,058.00View SEC Filing  
7/2/2015Jeffrey ChodakewitzCMOSell2,291$129.36$296,363.76View SEC Filing  
7/1/2015Joshua S BogerDirectorSell11,700$125.60$1,469,520.00View SEC Filing  
6/24/2015Joshua S BogerDirectorSell11,700$130.41$1,525,797.00View SEC Filing  
6/17/2015Joshua S BogerDirectorSell11,700$123.90$1,449,630.00View SEC Filing  
6/10/2015Joshua S BogerDirectorSell11,700$125.02$1,462,734.00View SEC Filing  
5/20/2015Joshua S BogerDirectorSell11,700$126.73$1,482,741.00View SEC Filing  
5/6/2015Joshua S BogerDirectorSell11,700$122.79$1,436,643.00View SEC Filing  
5/5/2015Paul M SilvaSVPSell4,101$123.68$507,211.68View SEC Filing  
4/29/2015Joshua S BogerDirectorSell11,700$124.59$1,457,703.00View SEC Filing  
4/27/2015Paul M SilvaSVPSell1,125$129.74$145,957.50View SEC Filing  
4/27/2015Stuart A ArbuckleEVPSell61,480$129.36$7,953,052.80View SEC Filing  
4/27/2015Terrence C KearneyDirectorSell68,125$129.11$8,795,618.75View SEC Filing  
4/22/2015Joshua S BogerDirectorSell11,700$132.46$1,549,782.00View SEC Filing  
4/15/2015Joshua S BogerDirectorSell11,700$129.25$1,512,225.00View SEC Filing  
4/13/2015Paul M SilvaSVPSell1,125$128.60$144,675.00View SEC Filing  
4/8/2015Joshua S BogerDirectorSell11,700$123.26$1,442,142.00View SEC Filing  
4/6/2015Margaret G McglynnDirectorSell12,500$118.36$1,479,500.00View SEC Filing  
4/2/2015Jeffrey ChodakewitzCMOSell2,291$115.50$264,610.50View SEC Filing  
4/1/2015Joshua S BogerDirectorSell11,700$115.87$1,355,679.00View SEC Filing  
3/25/2015Joshua S BogerDirectorSell11,700$120.76$1,412,892.00View SEC Filing  
3/23/2015Amit SachdevEVPSell17,083$132.28$2,259,739.24View SEC Filing  
3/23/2015Ian F SmithCFOSell6,042$125.67$759,298.14View SEC Filing  
3/23/2015Paul M SilvaSVPSell2,250$125.65$282,712.50View SEC Filing  
3/18/2015Amit SachdevEVPSell12,000$130.00$1,560,000.00View SEC Filing  
2/5/2015Paul M SilvaSVPSell1,688$109.75$185,258.00View SEC Filing  
2/4/2015Joshua S BogerDirectorSell5,700$108.81$620,217.00View SEC Filing  
2/3/2015Paul M SilvaSVPSell2,063$108.89$224,640.07View SEC Filing  
2/2/2015Jeffrey ChodakewitzCMOSell1,188$109.60$130,204.80View SEC Filing  
1/28/2015Joshua S BogerDirectorSell10,688$122.78$1,312,272.64View SEC Filing  
1/26/2015Paul M SilvaSVPSell1,125$125.62$141,322.50View SEC Filing  
1/21/2015Joshua S BogerDirectorSell10,500$125.08$1,313,340.00View SEC Filing  
1/14/2015Joshua S BogerDirectorSell10,500$120.16$1,261,680.00View SEC Filing  
1/9/2015Amit SachdevEVPSell12,000$125.00$1,500,000.00View SEC Filing  
1/9/2015Bruce I SachsDirectorSell9,861$125.04$1,233,019.44View SEC Filing  
1/7/2015Joshua S BogerDirectorSell10,500$119.32$1,252,860.00View SEC Filing  
1/2/2015Jeffrey ChodakewitzCMOSell2,291$122.54$280,739.14View SEC Filing  
12/22/2014Joshua S BogerDirectorSell10,500$117.65$1,235,325.00View SEC Filing  
12/17/2014Joshua S BogerDirectorSell10,500$110.66$1,161,930.00View SEC Filing  
12/15/2014Jeffrey M LeidenCEOSell50,017$114.97$5,750,454.49View SEC Filing  
12/12/2014Paul M SilvaSVPSell2,813$120.08$337,785.04View SEC Filing  
11/28/2014Amit SachdevEVPSell12,000$120.00$1,440,000.00View SEC Filing  
11/28/2014Bruce I SachsDirectorSell10,000$120.03$1,200,300.00View SEC Filing  
11/28/2014Paul M SilvaSVPSell8,164$119.85$978,455.40View SEC Filing  
11/26/2014Joshua S BogerDirectorSell10,500$114.54$1,202,670.00View SEC Filing  
11/6/2014Bruce I SachsDirectorSell9,900$115.21$1,140,579.00View SEC Filing  
11/5/2014Bruce I SachsDirectorSell30,100$112.62$3,389,862.00View SEC Filing  
11/3/2014Joshua S BogerDirectorSell127,411$112.20$14,295,514.20View SEC Filing  
10/29/2014Joshua S BogerDirectorSell10,500$109.44$1,149,120.00View SEC Filing  
10/28/2014Amit SachdevEVPSell12,000$115.00$1,380,000.00View SEC Filing  
10/28/2014David AltshulerDirectorSell2,000$114.75$229,500.00View SEC Filing  
10/28/2014Jeffrey ChodakewitzCMOSell3,438$115.00$395,370.00View SEC Filing  
10/27/2014Paul M SilvaSVPSell1,125$110.03$123,783.75View SEC Filing  
10/13/2014Paul M SilvaSVPSell1,125$107.89$121,376.25View SEC Filing  
10/7/2014Jeffrey ChodakewitzCMOSell3,436$104.26$358,237.36View SEC Filing  
10/6/2014David AltshulerDirectorSell1,405$109.75$154,198.75View SEC Filing  
10/1/2014Elaine UllianDirectorSell5,000$107.74$538,700.00View SEC Filing  
10/1/2014Stuart A ArbuckleEVPSell12,417$107.71$1,337,435.07View SEC Filing  
9/30/2014Amit SachdevSVPSell86,000$112.68$9,690,480.00View SEC Filing  
9/30/2014Ian F SmithCFOSell108,026$112.68$12,172,369.68View SEC Filing  
9/30/2014Jeffrey M LeidenCEOSell200,000$112.69$22,538,000.00View SEC Filing  
9/30/2014Kenneth L HortonEVPSell36,000$112.69$4,056,840.00View SEC Filing  
9/29/2014David AltshulerDirectorSell2,500$114.75$286,875.00View SEC Filing  
9/24/2014Joshua S BogerDirectorSell5,200$109.21$567,892.00View SEC Filing  
9/19/2014David AltshulerDirectorSell5,000$102.25$511,250.00View SEC Filing  
9/19/2014Paul M SilvaSVPSell25,408$99.85$2,536,988.80View SEC Filing  
9/19/2014Stuart A ArbuckleEVPSell55,521$100.00$5,552,100.00View SEC Filing  
9/17/2014Joshua S BogerDirectorSell5,200$93.62$486,824.00View SEC Filing  
9/10/2014Joshua S BogerDirectorSell5,200$94.42$490,984.00View SEC Filing  
9/5/2014David AltshulerDirectorSell2,500$94.75$236,875.00View SEC Filing  
9/3/2014Joshua S BogerDirectorSell5,200$92.79$482,508.00View SEC Filing  
8/27/2014Joshua S BogerDirectorSell5,200$93.31$485,212.00View SEC Filing  
8/20/2014Joshua S BogerDirectorSell5,200$91.51$475,852.00View SEC Filing  
8/13/2014Joshua S BogerDirectorSell5,200$88.00$457,600.00View SEC Filing  
8/6/2014Joshua S BogerDirectorSell5,200$86.54$450,008.00View SEC Filing  
7/31/2014David AltshulerDirectorSell5,000$89.59$447,950.00View SEC Filing  
7/31/2014Paul M SilvaSVPSell2,027$88.97$180,342.19View SEC Filing  
7/30/2014Joshua S BogerDirectorSell5,200$92.17$479,284.00View SEC Filing  
7/15/2014Wayne Joseph RileyDirectorSell4,800$96.65$463,920.00View SEC Filing  
7/1/2014Elaine UllianDirectorSell5,000$95.21$476,050.00View SEC Filing  
7/1/2014Kenneth L HortonEVPSell30,134$95.22$2,869,359.48View SEC Filing  
6/24/2014Megan E PaceSVPSell12,734$98.03$1,248,314.02View SEC Filing  
6/24/2014Wayne Joseph RileyDirectorSell15,000$98.03$1,470,450.00View SEC Filing  
6/16/2014Peter MuellerEVPSell7,500$68.31$512,325.00View SEC Filing  
6/9/2014Elaine UllianDirectorSell2,500$75.00$187,500.00View SEC Filing  
5/14/2014Peter MuellerEVPSell7,500$67.45$505,875.00View SEC Filing  
5/2/2014Megan PaceSVPSell1,000$67.62$67,620.00View SEC Filing  
4/15/2014Peter MuellerEVPSell7,500$61.63$462,225.00View SEC Filing  
4/9/2014Elaine UllianDirectorSell2,500$70.00$175,000.00View SEC Filing  
3/21/2014Bruce SachsDirectorSell8,700$74.59$648,933.00View SEC Filing  
3/17/2014Peter MuellerEVPSell7,500$78.29$587,175.00View SEC Filing  
2/7/2014Jeffrey LeidenCEOSell35,944$80.00$2,875,520.00View SEC Filing  
1/22/2014Bruce SachsDirectorSell8,300$84.47$701,101.00View SEC Filing  
1/21/2014Megan PaceSVPSell1,250$85.00$106,250.00View SEC Filing  
1/16/2014Jeffrey LeidenCEOSell45,000$80.00$3,600,000.00View SEC Filing  
1/15/2014Peter MuellerEVPSell7,500$78.67$590,025.00View SEC Filing  
12/23/2013Bruce SachsDirectorSell8,300$73.02$606,066.00View SEC Filing  
12/16/2013Peter MuellerEVPSell7,500$64.69$485,175.00View SEC Filing  
12/12/2013Jeffrey LeidenCEOSell9,834$65.48$643,930.32View SEC Filing  
12/12/2013Kenneth HortonEVPSell4,532$65.46$296,664.72View SEC Filing  
12/12/2013Megan PaceSVPSell5,083$65.48$332,834.84View SEC Filing  
12/4/2013Joshua BogerDirectorSell1,400$67.48$94,472.00View SEC Filing  
11/25/2013Joshua BogerDirectorSell1,400$66.89$93,646.00View SEC Filing  
11/20/2013Bruce SachsDirectorSell8,300$65.28$541,824.00View SEC Filing  
11/19/2013Joshua BogerDirectorSell1,400$62.31$87,234.00View SEC Filing  
11/5/2013Joshua BogerDirectorSell1,400$65.64$91,896.00View SEC Filing  
10/29/2013Joshua S BogerDirectorSell1,400$75.42$105,588.00View SEC Filing  
10/29/2013Thomas ConnollySVPSell1,688$75.04$126,667.52View SEC Filing  
10/24/2013Bruce I SachsDirectorSell8,300$77.06$639,598.00View SEC Filing  
10/23/2013Joshua S BogerDirectorSell1,400$76.77$107,478.00View SEC Filing  
10/16/2013Joshua S BogerDirectorSell1,400$75.41$105,574.00View SEC Filing  
10/15/2013Peter MuellerEVPSell7,500$73.25$549,375.00View SEC Filing  
10/14/2013Paul SilvaSVPSell1,593$71.87$114,488.91View SEC Filing  
10/9/2013Joshua BogerDirectorSell1,400$72.35$101,290.00View SEC Filing  
9/25/2013Joshua BogerDirectorSell1,400$74.72$104,608.00View SEC Filing  
9/18/2013Joshua BogerDirectorSell1,400$77.43$108,402.00View SEC Filing  
9/16/2013Peter MuellerEVPSell7,500$77.22$579,150.00View SEC Filing  
9/11/2013Joshua BogerDirectorSell1,400$79.61$111,454.00View SEC Filing  
9/4/2013Joshua BogerDirectorSell1,400$75.45$105,630.00View SEC Filing  
8/29/2013Bruce SachsDirectorSell8,300$77.19$640,677.00View SEC Filing  
8/28/2013Joshua BogerDirectorSell1,400$76.24$106,736.00View SEC Filing  
8/21/2013Joshua BogerDirectorSell1,400$76.96$107,744.00View SEC Filing  
8/15/2013Peter MuellerEVPSell7,500$77.41$580,575.00View SEC Filing  
8/14/2013Joshua BogerDirectorSell1,400$77.18$108,052.00View SEC Filing  
8/7/2013Joshua BogerDirectorSell1,400$77.84$108,976.00View SEC Filing  
8/5/2013Paul SilvaSVPSell3,001$78.90$236,778.90View SEC Filing  
7/31/2013Joshua S BogerDirectorSell1,400$80.89$113,246.00View SEC Filing  
7/29/2013Wayne Joseph RileyDirectorSell9,800$80.09$784,882.00View SEC Filing  
7/25/2013Paul M SilvaSVPSell1,125$86.49$97,301.25View SEC Filing  
7/24/2013Bruce I SachsDirectorSell8,300$85.50$709,650.00View SEC Filing  
7/19/2013Amit SachdevSVPSell22,250$88.69$1,973,352.50View SEC Filing  
7/18/2013Joshua S BogerDirectorSell1,400$86.12$120,568.00View SEC Filing  
7/16/2013Paul M SilvaSVPSell2,063$86.25$177,933.75View SEC Filing  
7/15/2013Christiana StamoulisSVPSell1,125$86.35$97,143.75View SEC Filing  
7/15/2013Peter MuellerEVPSell7,500$86.34$647,550.00View SEC Filing  
7/12/2013Megan E PaceSVPSell10,678$85.00$907,630.00View SEC Filing  
7/11/2013Joshua S BogerDirectorSell1,400$83.83$117,362.00View SEC Filing  
7/8/2013Kenneth L HortonEVPSell1,813$80.72$146,345.36View SEC Filing  
7/8/2013Megan E PaceSVPSell28,703$80.89$2,321,785.67View SEC Filing  
7/5/2013Christiana StamoulisSVPSell4,687$81.21$380,631.27View SEC Filing  
7/3/2013Joshua S BogerDirectorSell1,400$80.20$112,280.00View SEC Filing  
7/2/2013Peter MuellerEVPSell122,300$79.80$9,759,540.00View SEC Filing  
6/26/2013Joshua S BogerDirectorSell1,400$78.59$110,026.00View SEC Filing  
6/21/2013Bruce I SachsDirectorSell8,300$75.93$630,219.00View SEC Filing  
6/19/2013Joshua S BogerDirectorSell1,400$79.11$110,754.00View SEC Filing  
6/12/2013Joshua S BogerDirectorSell1,400$81.19$113,666.00View SEC Filing  
6/5/2013Joshua S BogerDirectorSell1,400$77.15$108,010.00View SEC Filing  
5/30/2013Joshua S BogerDirectorSell1,400$82.47$115,458.00View SEC Filing  
5/22/2013Joshua S BogerDirectorSell1,400$79.72$111,608.00View SEC Filing  
5/15/2013Joshua S BogerDirectorSell1,400$79.36$111,104.00View SEC Filing  
5/14/2013Bruce I SachsDirectorSell60,000$81.15$4,869,000.00View SEC Filing  
12/26/2012Joshua S BogerDirectorSell4,000$41.86$167,440.00View SEC Filing  
11/7/2012Margaret G McglynnDirectorBuy1,000$45.50$45,500.00View SEC Filing  
10/8/2012Ian F SmithCFOSell44,787$60.00$2,687,220.00View SEC Filing  
10/3/2012Joshua S BogerDirectorSell4,000$57.74$230,960.00View SEC Filing  
9/5/2012Joshua S BogerDirectorSell4,000$54.70$218,800.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
News IconVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Quarterly EPS At $0.47 - Stock Observer (NASDAQ:VRTX) - February 18 at 11:23 AM
News IconEquity Perception: Analyst's Indicator Review for Vertex Pharmaceuticals Incorporated (VRTX), Royal Caribbean ... - The USA Commerce (NASDAQ:VRTX) - February 18 at 11:23 AM
News IconRevenue Approximations Analysis: Vertex Pharmaceuticals Incorporated (VRTX), American Tower Corporation (AMT) - StockNewsJournal (NASDAQ:VRTX) - February 18 at 11:23 AM
News IconPulling Back The Curtain on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX): Analysts & Wall Street Chime In - Winfield Review (NASDAQ:VRTX) - February 17 at 6:59 AM
News IconWhy to Keeping Eye on Vertex Pharmaceuticals Incorporated (VRTX), TD Ameritrade Holding Corporation (AMTD)? - StockNewsJournal (NASDAQ:VRTX) - February 17 at 6:59 AM
News IconBrokerage Analysts Take Aim at Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - Rockville Register (NASDAQ:VRTX) - February 14 at 8:52 PM
News IconPeeling Back The Layers on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX): Analysts & Street Weigh In - Winfield Review (NASDAQ:VRTX) - February 14 at 8:52 PM
News IconAnalyst's Indicator Review for TransDigm Group Incorporated (TDG), Vertex Pharmaceuticals Incorporated (VRTX) - The USA Commerce (NASDAQ:VRTX) - February 14 at 3:50 PM
News IconAnalyst's Predictions on Omnicom Group Inc. (OMC), Vertex Pharmaceuticals Incorporated (VRTX) - StockNewsJournal (NASDAQ:VRTX) - February 13 at 9:55 AM
News IconReliable stocks in today's share market: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) (NASDAQ:VRTX) - February 12 at 11:40 PM
News IconAnalytical Guide for Vertex Pharmaceuticals Incorporated (VRTX), Waste Management, Inc. (WM) Stakeholders - The USA Commerce (NASDAQ:VRTX) - February 11 at 6:15 AM
News IconWhy to Keeping Eye on American Tower Corporation (AMT), Vertex ... - StockNewsJournal (NASDAQ:VRTX) - February 10 at 6:33 AM logoWhy Vertex Pharmaceuticals Stock Surged Higher in January (NASDAQ:VRTX) - February 10 at 6:33 AM
News IconRevenue Approximations Analysis: Capital One Financial Corporation (COF), Vertex Pharmaceuticals Incorporated ... - StockNewsJournal (NASDAQ:VRTX) - February 7 at 3:37 PM
News IconVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) from Biotechnology – Todays Top Gains (NASDAQ:VRTX) - February 4 at 6:11 AM
News IconLarge Cap Biotechnology: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) (NASDAQ:VRTX) - February 2 at 6:40 AM
News IconTop Gainers of the Day: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) from Biotechnology (NASDAQ:VRTX) - February 1 at 7:20 AM
News IconStock Buzz: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in Focus - Aiken Advocate (NASDAQ:VRTX) - January 31 at 2:16 AM
News IconTrading Radar: Checking Technicals for Vertex Pharmaceuticals Incorporated (VRTX) - Springdale Times (NASDAQ:VRTX) - January 30 at 9:58 AM
News IconLeading stocks in today’s market: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) (NASDAQ:VRTX) - January 29 at 5:16 AM
News IconInvestor Alert: Price Target Predictions for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - Aiken Advocate (NASDAQ:VRTX) - January 27 at 9:00 PM
News IconQuarterly EPS Of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Set At $0.92 - Stock Observer (NASDAQ:VRTX) - January 27 at 3:49 PM logoBlog Coverage Celgene Acquires Delinia; Set to Expand Inflammation and Immunology Portfolio (NASDAQ:VRTX) - January 27 at 3:49 PM logoBiotech M&A Activity Expected to Rise in 2017: Latest Reports on Exelixis and Vertex Pharmaceuticals (NASDAQ:VRTX) - January 27 at 3:49 PM logoPremarket Biotech Movers: Neurocrine Biosciences, Aralez Pharmaceuticals, Qiagen (NASDAQ:VRTX) - January 27 at 3:49 PM
News IconEarnings in Full Force, Analysts Take Aim at Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - Wall Street Beacon (NASDAQ:VRTX) - January 27 at 6:39 AM logoVertex Pharmaceuticals Incorporated Turns a Profit (NASDAQ:VRTX) - January 26 at 3:26 PM logoVERTEX PHARMACEUTICALS INC / MA Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statemen (NASDAQ:VRTX) - January 26 at 2:32 AM logoVertex Pharmaceuticals Incorporated : tops Street 4Q forecasts (NASDAQ:VRTX) - January 25 at 9:30 PM logoVertex Pharmaceuticals Inc. Reveals 100% Rise In Q4 Earnings (NASDAQ:VRTX) - January 25 at 9:30 PM logoQ4 2016 Vertex Pharmaceuticals Inc Earnings Release - After Market Close (NASDAQ:VRTX) - January 25 at 9:30 PM logoVertex Reports Full-Year and Fourth-Quarter 2016 Financial Results (NASDAQ:VRTX) - January 25 at 9:30 PM logo[$$] Vertex Pharmaceuticals Swings to Profit (NASDAQ:VRTX) - January 25 at 9:30 PM
News IconTechnical Trading Review on Shares of Vertex Pharmaceuticals Incorporated (VRTX) - Market Point (NASDAQ:VRTX) - January 25 at 4:24 PM logoWhy Vertex (VRTX) Might Surprise This Earnings Season - Nasdaq (NASDAQ:VRTX) - January 25 at 4:24 PM
News IconVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to Post $-0.01 Earnings Per Share: Analysts - Wall Street Beacon (NASDAQ:VRTX) - January 25 at 4:24 PM logoVertex tops Street 4Q forecasts (NASDAQ:VRTX) - January 25 at 4:24 PM logoWill These 5 Drug Stocks Be Big Winners in the Q4 Earnings Season? (NASDAQ:VRTX) - January 24 at 3:24 PM logoWhy Vertex (VRTX) Might Surprise This Earnings Season (NASDAQ:VRTX) - January 24 at 3:24 PM logoVertex Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VRTX-US : January 20, 2017 (NASDAQ:VRTX) - January 22 at 7:03 AM logoSeaport traffic gets dose of relief as Vertex joins shuttle program (NASDAQ:VRTX) - January 20 at 2:04 AM logoVertex Pharma (VRTX) Q4 Earnings: Stock Likely to Beat? - Nasdaq (NASDAQ:VRTX) - January 19 at 4:01 PM logoBlog Coverage Paratek Announced Enrollment Completion in Omadacycline Phase-3 Community-Acquired Bacterial Pneumonia Study (NASDAQ:VRTX) - January 19 at 4:00 PM logoVertex Pharma (VRTX) Q4 Earnings: Stock Likely to Beat? (NASDAQ:VRTX) - January 19 at 4:00 PM logoBaird Has 4 Red-Hot Biotechs to Buy for 2017 With Huge Upside Potential (NASDAQ:VRTX) - January 19 at 4:00 PM
News IconWorld Asset Management Inc Acquires 467 Shares of Vertex Pharmaceuticals Incorporated (VRTX) (NASDAQ:VRTX) - January 18 at 8:49 PM
News IconBiotechnology: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Position of the day (NASDAQ:VRTX) - January 18 at 8:49 PM
News IconShould one be buying Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)? (NASDAQ:VRTX) - January 18 at 8:49 PM
News IconLook out for Recommendations and Insider Activity: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) (NASDAQ:VRTX) - January 18 at 3:46 PM
News IconJohnson Investment Counsel Inc. Decreases Position in Vertex Pharmaceuticals Incorporated (VRTX) (NASDAQ:VRTX) - January 18 at 3:46 PM


What is Vertex Pharmaceuticals Incorporated's stock symbol?

Vertex Pharmaceuticals Incorporated trades on the NASDAQ under the ticker symbol "VRTX."

Where is Vertex Pharmaceuticals Incorporated's stock going? Where will Vertex Pharmaceuticals Incorporated's stock price be in 2017?

25 brokerages have issued twelve-month price targets for Vertex Pharmaceuticals Incorporated's stock. Their forecasts range from $75.00 to $139.00. On average, they expect Vertex Pharmaceuticals Incorporated's stock price to reach $102.28 in the next year.

When will Vertex Pharmaceuticals Incorporated announce their earnings?

Vertex Pharmaceuticals Incorporated is scheduled to release their next quarterly earnings announcement on Tuesday, April, 25th 2017.

What are analysts saying about Vertex Pharmaceuticals Incorporated stock?

Here are some recent quotes from research analysts about Vertex Pharmaceuticals Incorporated stock:

  • Cowen and Company analysts commented, "Last week we hosted meetings with Vertex management in Chicago." (2/11/2017)

  • Maxim Group analysts commented, "The global launch of Orkambi in the homozygote CF population continues to make progress, and growth is expected as more European countries come online. However, as we move through 2017, our attention is turning towards expected data in the heterozygote population, where we believe Vertex must be successful to drive long-term value." (2/3/2017)

  • According to Zacks Investment Research, "Vertex reported better-than-expected fourth-quarter 2016 results. Vertex has two cystic fibrosis (CF) drugs in its portfolio with blockbuster potential – Kalydeco & Orkambi. Its efforts to get the drugs approved for additional indications are encouraging. Label expansion will increase the patient population and boost sales. Vertex’s CF pipeline is also strong. However, we believe the 2017 Orkambi revenue guidance is below expectations and dependent on reimbursement discussions in Europe. Vertex expects that the upper end of the Orkambi sales guidance will be met only if it gets additional reimbursement and approvals in different European markets. Moreover, Vertex’s shares have consistently underperformed the Zacks categorized Biomed/Genetics industry in the past one year. Investor focus will now be on the triple combination CF regimens which are crucial for long-term growth at Vertex." (1/31/2017)

  • Needham & Company LLC analysts commented, "Vertex announced preliminary 2016 financial results and issued initial 2017 guidance last week. Total 2016 CF product revenues were $1.68B, in line with our $1.68B est. The company is scheduled to announce 2016 financial results 1/25/17. Guidance ($1.1-1.3B Orkambi and $690-700M Kalydeco) appears conservative, w/ mgmt. assuming flat Kalydeco sales and minimal Orkambi revenue growth next yr. Our new Orkambi and Kalydeco estimates are $1.41B (was $1.57B) and $716.0M (was $749.0M). Key milestones in 2017 include top-line results from Phase 3 trials of IVA/TEZ in 1H17 and initial Phase 2 triple combination (IVA/TEZ/VX-440 and IVA/TEZ/VX-152) data in 2H17." (1/20/2017)

  • HC Wainwright analysts commented, "Rare Find"The brokerage listed following four key factors to reach its conclusion on the stock:No change in underwhelming view on Orkambi.The 661/Kalydeco double is also not likely to perform better than Orkambi .Ongoing final stage program of 661 is not likely to yield any commercial upside.The expected triple combo continued to be far way.Even if triple combo is successful, it could only be a replacement and not complement Orkambi.The previous M&A thesis is at its lowest point of any likelihood.In a research note, the analysts stated, "We have all seen VRTX once before lose everything in the HCV space, in our view, due to failure to adapt to change and stay competitive. While we are not saying that a collapse of similar proportions is likely in CF, we nonetheless suspect that VRTX is no longer well positioned to remain the leader of the pack in the future." (10/24/2016)

Who owns Vertex Pharmaceuticals Incorporated stock?

Vertex Pharmaceuticals Incorporated's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (8.09%), State Street Corp (4.74%), Orbimed Advisors LLC (0.87%), Franklin Resources Inc. (0.58%), Fred Alger Management Inc. (0.55%) and Two Sigma Investments LP (0.41%). Company insiders that own Vertex Pharmaceuticals Incorporated stock include Amit Sachdev, David Altshuler, Elaine Ullian, Ian F Smith, Jeffrey Chodakewitz, Jeffrey M Leiden, Joshua S Boger, Margaret G Mcglynn, Paul M Silva, Stuart A Arbuckle, Terrence C Kearney and Yuchun Lee.

Who sold Vertex Pharmaceuticals Incorporated stock? Who is selling Vertex Pharmaceuticals Incorporated stock?

Vertex Pharmaceuticals Incorporated's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Fred Alger Management Inc., Thrivent Financial for Lutherans, Janus Capital Management LLC, GLG LLC, Employees Retirement System of Texas, NN Investment Partners Holdings N.V. and New York State Teachers Retirement System. Company insiders that have sold Vertex Pharmaceuticals Incorporated stock in the last year include Amit Sachdev, Ian F Smith, Joshua S Boger, Paul M Silva and Stuart A Arbuckle.

Who bought Vertex Pharmaceuticals Incorporated stock? Who is buying Vertex Pharmaceuticals Incorporated stock?

Vertex Pharmaceuticals Incorporated's stock was bought by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Orbimed Advisors LLC, Baillie Gifford & Co., Asset Management One Co. Ltd., State Street Corp, AMF Pensionsforsakring AB, AQR Capital Management LLC and FIL Ltd.

How do I buy Vertex Pharmaceuticals Incorporated stock?

Shares of Vertex Pharmaceuticals Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Vertex Pharmaceuticals Incorporated stock cost?

One share of Vertex Pharmaceuticals Incorporated stock can currently be purchased for approximately $88.33.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Chart for Tuesday, February, 21, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Earnings History Chart

Earnings by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Dividend History Chart

Dividend Payments by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Last Updated on 2/21/2017 by Staff